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Activated G protein-coupled receptors (GPCRs) and receptor tyro-
sine kinases relay extracellular signals through spatial and temporal
controlled kinase and GTPase entities. These enzymes are coordi-
nated by multifunctional scaffolding proteins for precise intracellu-
lar signal processing. The cAMP-dependent protein kinase A (PKA)
is the prime example for compartmentalized signal transmission
downstream of distinct GPCRs. A-kinase anchoring proteins tether
PKA to specific intracellular sites to ensure precision and direc-
tionality of PKA phosphorylation events. Here, we show that
the Rho-GTPase Rac contains A-kinase anchoring protein proper-
ties and forms a dynamic cellular protein complex with PKA. The
formation of this transient core complex depends on binary inter-
actions with PKA subunits, cAMP levels and cellular GTP-loading
accounting for bidirectional consequences on PKA and Rac down-
stream signaling. We show that GTP-Rac stabilizes the inactive PKA
holoenzyme. However, β-adrenergic receptor-mediated activation
of GTP-Rac–bound PKA routes signals to the Raf-Mek-Erk cascade,
which is critically implicated in cell proliferation. We describe a fur-
ther mechanism of how cAMP enhances nuclear Erk1/2 signaling: It
emanates from transphosphorylation of p21-activated kinases in
their evolutionary conserved kinase-activation loop through GTP-
Rac compartmentalized PKA activities. Sole transphosphorylation
of p21-activated kinases is not sufficient to activate Erk1/2. It requires
complex formation of both kinases with GTP-Rac1 to unleash
cAMP-PKA–boosted activation of Raf-Mek-Erk. Consequently GTP-
Rac functions as a dual kinase-tuning scaffold that favors the PKA
holoenzyme and contributes to potentiate Erk1/2 signaling. Our
findings offer additional mechanistic insights how β-adrenergic re-
ceptor-controlled PKA activities enhance GTP-Rac–mediated activa-
tion of nuclear Erk1/2 signaling.
signal transduction | cross-talk
Signal transduction cascades coordinate the plethora of extra-cellular stimuli into biological responses within cells. The spec-
ificity of receptor-initiated signaling responses is encoded by spatial
and temporal dynamics of downstream signaling networks (1).
These networks, initiating frome.g., theGprotein-coupled receptor
(GPCR) superfamily and receptor tyrosine kinases (RTK), tightly
regulate signaling pathways at several critical points via feedback
loops and cross-talk among other pathways (2–5).A large numberof
GPCR signaling cascades uses cAMP as an intracellular second
messenger (3, 6). In response to hormone binding to distinct
GPCRs, cAMP is produced and binds to its canonical effector, the
cAMP-dependent protein kinase A (PKA). cAMP binding to the
PKA regulatory subunits (R) induces dissociation of the tetrameric
PKAholoenzyme, resulting in active PKAcatalytic subunits (PKAc;
Fig. 1C) (7, 8). To ensure substrate specificity, PKA is tethered to
distinct subcellular compartments through physical interaction with
A-kinase anchoring proteins (AKAPs; refs. 9 and 10). It has been
long regarded that the GPCR-cAMP-PKA signaling axis partic-
ipates, among others, in the regulation of cell growth, differentia-
tion, and motility (9–13). Such fundamental cellular functions are
controlled by mitogenic signals that are transmitted through cas-
cades involving crucially regulated mitogen-activated protein kina-
ses (MAPK) like Erk1/2 (14). It has been described that the Rho
GTPase Ras-related C3 botulinum toxin substrate 1 (Rac1) par-
ticipates in the regulation of transformation, growth, and survival of
tumor cells at least partially by controlling extracellular signal-reg-
ulated kinase (Erk)1/2 activation (15, 16). So far, several function-
ally diverse means have been illustrated how hormone-triggered
cAMP pulses participate in the regulation and transmission of
mitogenic signals originating from RTK via the Raf-Mek-Erk
pathway (11–13). At different stages of RTK-mediated signal
transmission, these pathways interact to regulate proliferation.
Cross-talk originates from trimeric G protein switching [at the
GPCR level: shown for the β-2 adrenergic receptor (β2AR)],
through different mode of actions of cAMP-PKA on G proteins
like Ras-related protein 1 (Rap1) and inhibitory G protein alpha
i (Gαi) and by modulation of the proto-oncogene Raf1 (13, 17–
20). In addition, scaffolding proteins like AKAP-Lbc, phosphor-
ylation of phosphodiesterases and phosphatases contribute to this
cross-talk related to MAPK signaling (21–23). Moreover, the
mentioned β2AR pathway (3, 6) leading to cAMP-PKA activation
has been implicated in malignant cell growth in a mouse model of
ovarian carcinoma (24). Here, we examine a unique mechanism
how cAMP-activated PKA is involved in the regulation of Erk1/2
activities. We report that Rac1, a member of the Rho GTPase
family (25), contains AKAP properties and, thus, show direct
interactions with PKA R subunit type IIβ (RIIβ) in vitro and in
vivo. Our cell-based studies demonstrate that complex formation
of active GTP-Rac1 and PKA increase inactive PKA complexes
but does not directly affect Rac1 GTPase activity. However, we
unveil that βAR-activated PKA phosphorylates the main Rac-
effectors, p21-activated kinases (PAKs), which leads toGTP-Rac1–
dependent elevation of downstream signaling to Erk1/2. We de-
scribe a mechanism through which PKA, a key component of
cAMP-GPCR cascades, participates in the regulation of RTK-ac-
tivated Rac-PAK-Erk1/2 signaling to nuclear transcription factors.
Results
PKA RII Subunits Form Protein Complexes with Rac1 in Vitro and in
Vivo.We performed a systematic screen using a “Venus” yellow
fluorescent protein (YFP) protein-fragment complementation
assay (PCA) in mammalian cells to identify transient protein:
protein interactions emanating from PKA R subunits with
downstream components of RTK and GPCR cascades (18). We
identified interaction of PKA RIIβ with the small Rho family
GTPase Rac1 (Fig. 1A). The PKA homodimer RIIβ:RIIβ was re-
stricted to the cytosol, but both the Rac1:Rac1 homodimer and the
identifiedRac1:RIIβ complex were primarily localized to the plasma
membrane (Fig. 1B). This observation highlights physical connection
between PKA and Rac1, which are key effectors of canonical re-
ceptor cascades, e.g., of the GPCR and RTK family, respectively
(Fig. 1C). We confirmed direct protein:protein interaction of Rac1:
RIIβ by using two independent in vitro tests: First, we confirmed
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direct interaction in a far Western blot analysis by using the
recombinant full-length and untagged proteins RIIβ, Rac1 and,
serving as negative controls, the recombinant geminin binding
domain (GBD) and glutathione S-transferase (GST) (Fig. 1D).
Second, we showed direct interaction of recombinant RIIβ and
Rac1 in cAMP precipitation assays (Fig. S1A). To analyze whether
the Rac1:R-subunit complex exists under physiological conditions,
we applied total brain lysates of mice to Rp-8-AHA-cAMP–cou-
pled agarose beads (precipitates R:PKAc holoenzymes). Isolated
PKA complexes coprecipitate endogenous Rac1 (Fig. 1E). Addi-
tionally, we isolated Rac1:R-subunit complexes from the ovarian
cancer cell line OVCAR3 and HeLa cells, respectively (Fig. S1B).
Impact of PKA Activation on GTPase Activity and RII:Rac1 Complex
Formation. Upon exposure to mitogenic stimuli, Rho GTPases are
converted to active GTP-bound forms that interact and activate
downstream effectors like the p21-activated kinases (PAK1–6)
(26, 27). We used purified PAK binding domain (PBD; exclusive
binding site for GTP-Rac1) to determine theGTP loading of Rac1.
Treatment of HEK293 cells with Forskolin, which triggers general
cAMP elevation and PKA activation, had no significant impact on
the GTPase activity of endogenous Rac1 (Fig. 1F). We confirmed
this observation with ectopically expressed Rac1 variants: wild-
type, dominant negative (T17N) and constitutively active (Q61L)
Rac1-YFP (ref. 28; Fig. S1 C and D). We next precipitated en-
dogenous cellular proteins by using GST and GST-RIIβ from
HEK293 cells following treatment with Forskolin. As predicted, we
detected a decrease of affinity betweenGST-RIIβ and PKAc. Next,
we confirmed binding of endogenous Rac1 to GST-RIIβ. Upon
cAMP elevation, we observed a decrease of GST-RIIβ:Rac1
complexes, suggesting that Rac1 interacts preferentially with the
inactive PKA holoenzyme (Fig. 1G and Fig. S1E).
Analyses of Binding Regions of RIIβ on Rac1 and Related GTPases. To
map the interaction sites on Rac1, we performed a peptide
spotting experiment of Rac1b to confirm interaction in vitro and
to determine specific amino acids required for RIIβ binding
(18). We identified two potential binding sites located at the C
terminus of Rac1, in regions distinct from GTPase-activity sites
(“switch regions”; Fig. 2A and Fig. S1F). In theRac1 structure, we
highlight two binding sites (BD1 and BD2) located in close vi-
cinity to permit protein:protein interaction with RIIβ (Fig. 2B,
Left). We allocated an amphipathic helix motif (BD2) almost
matching with a described consensus site for RII-binding domains
(RIIBD) found in other AKAPs [Fig. 2B, Right; red brackets and
red F (Phenylalanine) indicate the difference; ref. 29]. Structural
and detailed biochemical analyses have specified that amino acids
1–45 of RIIβ cover the primary determinants for binary protein:
protein interaction of R subunits with AKAPs (30, 31). We con-
firmed that the first 45 amino acids of RIIβ are sufficient to interact
with full-length Rac1 (Fig. 2C). Next, in aGST-pulldown experiment
with GST and GST-BD2 hybrid proteins, we precipitated endoge-
nous RIIβ from HEK293 cells independent from altering cAMP
levels (Fig. 2D). Next, we tested conserved members of the Rho
GTPase family for AKAP properties (Fig. S2A) (32). We observed
that substitutions of amino acids in the nonpolar region of BD2 are
sufficient to decrease the affinity between GST-RIIβ and peptide
mutants of Rac1/2/3. Surprisingly, we detected interaction of human
RIIβ at least with the Saccharomyces cerevisiae Rho GTPase Rho1
(Fig. 2E). To further characterize the RII binding sites in Rac1, we
performed alanine substitution scanning of BD1 and BD2 to identify
key amino acids responsible for the interaction (Fig. S2 B and C).
Following structural examination of BD1 in Rac1 and based on the
alanine substitution experiment, we generated the GTP-Rac1
mutants Q61L-A1 (H104A, P106A) andQ61L-A2 (T108A, P109A).
Moreover, we disrupted the C-terminal amphipathic helix of BD2 of
GTP-Rac1 and generated the Q61L-P mutant (I173P). Exchange of
I173P abolished binding of Q61L-P to both GST-RIIβ and GST-
PBD. In contrast, A1 mutations of BD1 in GTP-Rac1 (Q61L-A1)
had no impact on PBDbinding but showed a slight reducing effect on
complex formation of GTP-Rac1:RIIβ (Fig. 2F). These results
support the notion that both binding domains of Rac1 are in-
volved in the formation of cellular complexes with RIIβ.
GTP-Rac1 Stabilizes the PKA Holoenzyme. To get insights whether
PKA RIIβ subunits have different affinities for the mentioned
Rac1-YFP variants, we performed GST-pulldown experiments.
We observed preferential binding of GST-RIIβ to cellularly
expressed GTP-Rac1 (Q61L) (Fig. 3A and Fig. S3A). This result
underlines that PKA preferentially binds to cellular GTP-Rac1
complexes that exist bound to downstream effectors like PAKs.
First, we evaluated the effect of GTP-Rac1 overexpression on
PKA activity. We transiently overexpressed indicated variants of
Rac1 in the osteosarcoma cell line U2 (U2OS) and in HEK293
cells, which both stably express the Rluc-PCA based PKA re-
porter (Fig. 3B; ref. 33). Exclusively, the overexpression of GTP-
Rac1 (Q61L) increased the inactive complex of RIIβ:PKAc in
transient transfections in both cell lines significantly approxi-
mately 50% (Fig. 3B). Following the analyses of the impact of
GTP-Rac1 on PKA signaling, we set the focus on investigating
the influence of PKA activities on Rac1 downstream signaling to
the nucleus.
cAMP-Dependent Regulation of GTP-Rac1 Signaling to Erk1/2. It has
been reported that Rac1 participates to promote the Raf-Mek-
Erk cascade (16, 34–36). To investigate the role of GTP-Rac1 in
Erk1/2 activation, we used HEK293 cells, which show no in-
crease of Erk1/2 phosphorylation in response to Forskolin alone
(18). We confirmed observations that exclusively the overex-
pression of the constitutive active GTP-Rac1 variant activates
Erk1/2 (16) (Fig. 3C). Activation of Erk1/2 causes activation
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Fig. 1. PKA regulatory subunits form complexes with Rac1 in vitro and in
vivo. (A) PCA strategy to capture binary protein complexes in living cells.
Fluorometric analysis of transiently transfected HEK293 cells coexpress-
ing indicated protein couples (fluorescence spectroscopy; representative
of n = 3, ±SEM). (B) Fluorescence images of HEK293 cells expressing in-
dicated PCA protein couples. (Scale bars: 10 μm.) (C ) Schematic repre-
sentation of ligand-activated receptor pathways (GPCR, RTK). Blue arrow
indicates physical interaction (pm, plasma membrane). (D) Far western blot
illustrates direct binding of RIIβ to Rac1 (representative of n = 3). (E) cAMP
precipitation of PKA complexes using Rp-8-AHA-cAMP agarose resin from
total brain lysates of mice (representative of n = 3). (F) GTPase measurements
of endogenously expressed Rac1 following Forskolin exposure (100 μM; n = 5,
±SEM; HEK293). (G) GST pulldown of Rac1 and PKAc following general cAMP
elevation (Forskolin, 100 μM; n = 4, ±SEM; HEK293).
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of nuclear transcription factors like Elk1. We observed that
ectopic expression of GTP-Rac1 further enhances activation
of gene transcription by Erk1/2-mediated Elk1 phosphoryla-
tion (Fig. 3D). Next, we tested the impact of cAMP elevation
on Erk1/2 activity. We observed that cAMP elevation enhan-
ces Erk1/2 activation exclusively in the presence of GTP-Rac1
to above threefold (Fig. 3E). We tested the GTP-Rac1 mu-
tants presented in Fig. 2F for interference with signaling to
Erk1/2. We observed that the GTP-Rac1 mutant Q61L-A1 pre-
vented Forskolin-mediated Erk1/2 activation. This observation
underlines that BD1 in Rac1 participates to permit cAMP-
PKA–mediated Erk1/2 activation (Fig. 3F and Fig. S3B).
However, to confirm that PKA kinase activity accounts for po-
tentiating Erk1/2 phosphorylation in the presence of GTP-Rac1,
we pretreated cells with the selective PKA inhibitor KT5720.
PKA inhibition prevents the Forskolin-mediated potentiation of
Erk1/2 phosphorylation (Fig. S3C). To analyze whether GPCR
cascades linked to cAMP production participate in the regula-
tion of GTP-Rac1 signaling to Erk1/2, we tested the involvement
of the β2AR that, among other vital cellular functions, has also
been linked to aberrant proliferation (3, 6, 24). As already known,
the β-adrenergic agonist Isoproterenol (Iso) induces a transient
increase of Erk1/2 phosphorylation in HEK293 cells stably ex-
pressing the β2AR. Isoproterenol-triggered activation of ERK1/2
is mediated via pathways that are sensitive to both the PKA in-
hibitor H89 and Gαi inhibitor pertussis toxin (37). In addition,
it has been described that GPCR-bound β-arrestin participates
in signaling to Erk1/2 (38). Isoproterenol treatment of HEK293-
β2AR cells transiently overexpressing GTP-Rac1 further potenti-
ated Erk1/2 phosphorylation (Fig. 3G). These data support the
notion that β2AR provoked cAMP release and subsequent acti-
vation of GTP-Rac1–bound PKA further promotes activation of
Erk1/2 as illustrated with the blue arrows in the scheme.
PKA Activities Affect p21-Activated Kinase Signaling to Erk1/2. First,
we confirmed other studies that Rac1 is no direct target for
PKAc phosphorylation, using the PKA substrate RhoA as posi-
tive control (39) (Fig. 4A). We aimed to identify the target of
PKA phosphorylation, which links GTP-Rac1 to Erk1/2 activi-
ties. In Fig. 3A, we demonstrate that cellular GTP-Rac1 com-
plexes have the highest affinity for the PKA holoenzyme. The
key effector and conserved interacting partner of active GTP-
Rac1 are PAKs: PAK1–6 (26, 27, 40). It has been described that
PAK1 is phosphorylated by PKA (41). Sequence alignment and
phosphorylation prediction highlight the existence of a PKA
consensus site in the evolutionary conserved activation loop of
PAKs (Fig. 4B). This highly conserved site can be found in the
activation loop of PKAc subunit as well (Thr197). In both cases,
autophosphorylation has been confirmed upon kinase activation
(42, 43). In Fig. 4B, we highlight structural conservation. Just
recently Park et al. (44) showed that PKAc subunits form pro-
tein complexes with its substrate PAK4. That is why we hy-
pothesized that physical association of GTP-Rac1 with both
kinases, PKA and PAKs, accounts for the observed GTP-Rac–
and PKA-dependent Erk1/2 activation. First, we confirmed the
possibility of physical interaction of PKAc subunits with PAK1
in dot blot analyses. We identified two preferential stretches of
interaction close to the PKA consensus site for phosphorylation
in the ultimate C terminus of PAK1 (Fig. S3 D and E). These
results indicate that interaction of PKAc:PAK might be involved
in stabilizing the interaction of the PKA holoenzyme with Rac1
variants (Figs. 1G, 2F, and 3 A and B). Next, in two independent
cell systems, we tested whether PKA activation causes PAK
phosphorylation, which has been described to modulate Raf-
Mek-Erk signaling (16, 34–36): First, we show that both over-
expression of PKAc and Forskolin treatment elevates PAK1-
Thr423 and PAK2-Thr402 phosphorylation (Fig. S4A). Next,
we analyzed whether type II PAKs (PAK4–6) are targets of
PKA as well. Upon general cAMP elevation and following
activation of β2AR (Iso), we observed significant elevations of
PAK4-Ser474 phosphorylation in the absence and presence of
indicated Rac1 versions. Overexpression of GTP-Rac1 causes
basal levels of PAK4-Ser474 phosphorylation, which can be fur-
ther raised by PKA activation (Fig. 4C). However, PKA-mediated
PAK4 phosphorylation is not sufficient to promote downstream
Erk1/2 activation. These data highlight that PKA activities in the
A E
B
C
F
D
Fig. 2. Analyses of binding regions of RIIβ on Rac1
and related GTPases. (A) Colored bars point to the
sequences of binding domains (BD1/BD2) obtained
by dot blot analyses for RIIβ subunits in the modular
structure of Rac1 (n = 3, ±SEM). (B) Structure of
Rac1 (PDB ID code 1E96) illustrating the localization
of BD1, BD2, and GTP. RIIBD consensus motif of
AKAPs (29) and helical wheel projection of the
amphipathic BD2 of Rac1. (C) Coomassie Brilliant
Blue (CBB) staining of RIIb1-45-his6 and a far western
blot experiment. (D) GST pulldown of cellular RIIβ
using indicated GST hybrid proteins (±100 μM For-
skolin, 15 min; shown are independent samples). (E)
Dot blot analysis of Rho GTPases peptides. Ex-
changed amino acids are indicated with red letters
(average of n = 2). (F) Interaction studies of in-
dicated GTP-Rac1 variants in biochemical GST pull-
down assays (±SEM, n = 4).
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presence of GTP-Rac1 further enhance PAK phosphorylation,
which elevates GTP-Rac:PAK signaling to Erk1/2 (Fig. S4B).
Next, we tested GTP-Rac1 mutants for interference with signaling
to PAK4 and Erk1/2. We detected that basal enhancements of
Erk1/2 and PAK4-Ser474 phosphorylations are comparable in
the presence of Q61L or Q61L-A1. However, we observed that
compared with GTP-Rac1 (Q61L), the mutant Q61L-A1 sig-
nificantly reduced Isoproterenol-mediated Erk1/2 and PAK4-
Ser474 phosphorylation. This observation underlines that BD1
of GTP-Rac1 participates to boost β2AR-controlled and
cAMP-PKA–mediated PAK4 and Erk1/2 phosphorylation (Fig.
4D). Therefore, we conclude that PAK activities are controlled also
through a third condition: First, PAKs need to be phosphorylated
in the activation loop. Second, PAKs need to bind GTP-Rac1 to
allow signal transmission to Erk1/2. Third, our data support the
notion that GTP-Rac1–compartmentalized and cAMP-activated
PKA participates in phosphorylating PAKs in their activating
loops, thereby contributing to the progression of Rac-PAK-Erk
signaling. Further, we revealed an additional connection from
βAR cascades to Erk1/2 activities. We present evidence that
β2AR-controlled cAMP-PKA activation participates in GTP-
Rac1:PAK–initiated Erk1/2 phosphorylation. It has been described
that in an ovarian carcinoma mouse model, activation of the
β2AR-PKA signaling axis contributes to tumor growth (24). In
another study, it has been shown that PAK4 activities regulate
ovarian cancer cell proliferation, migration, and invasion (45).
Therefore, we decided to analyze one human ovarian cancer cell
line (OVCAR3) from this study (45) for the involvement of βAR-
PKA and PAK4/6 signaling in Erk1/2 activation and proliferation.
First, we demonstrate basal levels of PAK4-Ser474 and PAK6-
Ser560 phosphorylation in OVCAR3 cells. Upon cAMP elevation
with Forskolin and Isoproterenol, we confirmed elevation of
PAK4/6 phosphorylation (Fig. 4E and Fig. S4C). Isoproterenol
activates selectively endogenously expressed βAR, which led to
activation of Erk1/2 and Elk1 (Fig. 4E). PKA inhibition pre-
vented Isoproterenol-initiated PAK4/6, Erk1/2, and Elk1 phos-
phorylation (Fig. 4E). These findings link βAR pathways to the
activation of the proliferation relevant PAK-Erk-Elk1 cascade.
Next, we performed cellular proliferation assays (18 h) to test
how far βAR activities and scaffolding complexes like RII:
Rac1 are relevant for proliferation. Activation of βAR cas-
cades showed a significant enhancement of proliferation of
OVCAR3 cells (Fig. 4F, doubling time of 4 d; ref. 46). In addi-
tion, we tested membrane permeable AKAP:PKA disrupting
peptides (Fig. S4D), which significantly reduced proliferation (Fig.
4F). The peptides (in the used concentration of 10 μM) showed
no impact on the formation of the PKA–holoenzyme complex
(Fig. S4E). These results support the notion that βAR-con-
trolled PKA activities contribute to proliferative effects by ac-
tive participation in the GTP-Rac:PAK signaling axis leading to
Erk1/2 phosphorylation and activation of the nuclear tran-
scription factor Elk1. Overall, our observations highlight a bi-
directional function of the Rac1:PKA complex. GTP-Rac1
enriches and compartmentalizes inactive PKA complexes through
binary interaction with RII subunits. However, the three-part
complex of PKA:GTP-Rac1:PAKs acts as compartmentalized
modulator of Erk1/2 activities that is controlled first by GTP
loading, second through physical interaction with both kinases
(PKA and PAK), third through PAK activities, and last but not
least through βAR-triggered cAMP-PKA activities (Fig. 4G).
Discussion
Rac1 belongs to the Rho GTPase family of small GTP-binding
proteins. Prominent members of this family Rho, Cdc42, and Rac
emerge to regulate a diverse array of cellular events, including
control of the reorganization of the cytoskeleton, cell growth, and
activation of diverse protein kinases (25).Wenow report that Rac1
contains AKAP properties and directly interacts with PKA RII
subunits. Complex formation of RII:Rac1 is not static; it depends
on cellular GTP loading, bound Rac effectors, and cAMP eleva-
tion, and it accounts for bidirectional consequences on signal
transmission. We describe a mode of regulation that is comple-
mentary to the regulation by guanine exchange factors (GEFs),
GTPase activating proteins (GAPs), and guanine dissociation
inhibitors. We show that cAMP elevation has no direct impact on
Rac1GTPase activities and, therefore,GTP loading. First, our data
reveal that complex formation of cellular GTP-Rac1 with PKARII
subunits stabilizes the inactive PKA holoenzyme. Second, we show
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Fig. 3. Reciprocal regulation of PKA and GTP-
Rac1 signaling. (A) Complex formation of GST-RIIβ
and Rac1-YFP variants (±SEM, n= 3, normalized on
the input). (B) Impact of indicated Rac1 versions on
the formation of the RIIβ:PKAc complex in HEK293
and U2OS cells stably expressing the Rluc-PCA PKA
sensor (representatives of n = 3, ±SEM). (C) Impact
of overexpression of Rac1 versions on protein
abundance and Erk1/2 phosphorylation. Scheme
highlights GTP-Rac1 signaling to Erk1/2. (D) Effect
of transient overexpression of indicated Rac1 ver-
sions on transcription factor Elk1 activation (n = 5,
±SEM, Elk1 activity luciferase reporter assay). (E)
Effect of Rac1 version overexpression on Forskolin-
mediatedErk1/2 phosphorylation (n= 3,±SEM). (F)
Effect ofGTP-Rac1 (Q61L,Q61L-A1) overexpression
on Forskolin-mediated Erk1/2 phosphorylation
(n = 5, ±SEM). (G) Impact of Rac1 overexpression
and Isoproterenol treatment on Erk1/2 phos-
phorylation (β2AR-HEK293; n = 3, ±SEM).
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that active GTP-Rac1 augments Erk1/2 phosphorylation, which
causes subsequent activation of the transcription factor Elk1.
Third, we demonstrate that the activity of the GTP-Rac1:PAK
signaling axis leading to activation of Erk1/2 can be directly con-
trolled through GTP-Rac1–compartmentalized PKA activities.
Fourth, we have revealed that in the ovarian cancer cell line
OVCAR3, the proliferation-relevant βAR-PKA signaling axis (24,
47) is linked to Rac-PAK-Erk1/2-mediated activation of the
transcription factor Elk1. Overall our findings disclose a unique
crossroad of frequently targeted receptor cascades (RTK, βAR)
that integrates cAMP responses and GTPase activities spatially
and temporally, leading to modulation of the crucial Raf-Mek-Erk
signaling axis (11–16). It has been described that PKA activities
regulate GEFs and GAPs that change the GTP loading of Rac1,
resulting in changes of signaling related to morphological alter-
ations of the cytoskeleton (48–50). These processes are distinct
from the mechanism we describe here, where Rac-anchored PKA
activities directly contribute to the activation of downstream
effectors of GTP-Rac signaling leading to Erk1/2 activation. An-
other GTPase, which we have identified in the same screen to be
a binary interaction partner of PKA RII subunits, is a component
of the trimeric G protein complex Gαi, although without AKAP
features (18). In contrast to Rac1:PKA, complex formation of RII
subunits with Gαi was observed in response to cAMP elevation.
Indeed, mechanistically different, the appearance of cAMP-RII:
Gαi elevates GPCR-mediated downstream signaling leading,
among others, to Erk1/2 activation. Rac1 is not the first small
GTPase with AKAP properties. The GTPaseRab32 is classified as
an AKAP and targets PKA activities to the mitochondrion. In-
terestingly, another scaffolding protein with AKAP properties,
WAVE-1, directs actin reorganization by relaying signals from the
GTPaseRac to downstreameffectors.Overall severalAKAPs (like
AKAPlbc or AKAP220) group PKA, other Rho GTPases, and
their regulator molecules together, thereby regulating small
GTPase activities affecting cytoskeleton reorganizations (9, 10, 48,
51). Severalmeans have been described how the secondmessenger
cAMP alters signaling through the Ras-Raf-Erk cascade positively
or negatively. However, it is still a controversy how cell type-
dependent components of the cAMP machinery (PKA, AKAPs,
Epac, PDEs) contribute to these opposed consequences on Erk1/2
activation that lead to cell growth and/or aberrant proliferation
(11–13, 17–23, 52, 53). Here, we present a mechanism how GPCR
and cAMP-mediated PKA activation regulates GTP-Rac1 signal-
ing via Erk1/2 to nuclear transcription factors. The detailed
mechanism of Rac1-mediated Erk1/2 activation has been de-
scribed: GTP-Rac1 endorses Raf-Mek-Erk signaling by PAK-
mediated phosphorylation of Raf at Ser338 or of Mek at Ser298,
which promotes interaction between Erk and Mek (16, 34–36). A
link between PKA activities and Rho GTPase-PAK1 signaling has
been discovered more than a decade ago (41). Just recently, it has
been depicted that PKAc subunits form a protein complex with
PAK4 (44), which we confirmed with PAK1 (Fig. S3 D and E).
First, this observation is one possible explanation how cellular
GTP-Rac1 stabilizes the PKA holoenzyme by improved affinities
of cellular GTP-Rac:PAKs for RIIβ:PKAc (Fig. 3 A and B). Sec-
ond, this data underlines the concept of compartmentalization of
PKA through interaction with the GTP-Rac1:effector complex. In
agreement with Park et al. (44), we show that PAK4 is a target of
PKA activity by phosphorylating the conserved kinase activation
loop (Fig. 4). We link GTP-Rac1–compartmentalized PKA activ-
ities, initiated directly by adenylyl cyclase or βAR activation, to the
phosphorylation of PAK isoforms. This PKA phosphorylation
event contributes to sustained elevations of Erk1/2 activities that
implicates enhanced proliferation. Of note in this work is that sole
transphosphorylation of PAK4 in its activation loop is not sufficient
to promote Erk1/2 activation (Fig. S4B). It requires the complex
formation of compartmentalized and PKA-phosphorylated
PAK4 with GTP-Rac1, which acts as an active kinase-tuning
scaffold [in positive (PAKs) or negative manner (PKA)] to un-
leash cAMP-PKA–controlled Erk1/2 activation (Fig. 4G), which
can be prevented by introducing mutations into BD1 of GTP-
Rac1 (Fig. 4D). PAKs are key effectors central to numerous
A C E F
B D
G
Fig. 4. βAR-PKA axis participates in PAK signaling. (A) PKA phosphorylation of indicated peptides. (B) Modular structure of PAKs with potential PKA
phosphorylation site. Structural alignment of PAK4 and PKAc activation loops (PDB ID codes: 2CDZ/1BKX) with indication of Ser474 and Thr197. (C) PAK4
phosphorylation upon overexpression of Rac1-versions (Iso, 10 μM; Forskolin, 50 μM; 15 min, HEK293). (D) Effect of GTP-Rac1 (T17N, Q61L, Q61L-A1) over-
expression on Iso-mediated Erk1/2 and PAK4-Ser474 phosphorylation (n ≥ 4, ±SEM, 5 min, 10 μM). Statistical significance was assessed by using a paired
Student t test (##P < 0.01). (E) Impact of PKA inhibition (KT5720: 1 h, 5 μM) and Iso exposure (15 min, 1 μM) on PAK4/PAK6 phosphorylation (±SEM, n = 3,
OVCAR3). (F) Proliferation assay of OVCAR3 cells following 18 h of Iso (1 μM), ICI118.551 (2 μM; β2AR antagonist), and AKAP18δ peptides (10 μM) exposure
(n = 6, ± SEM). Statistical significance was assessed by using a paired Student t test (#P < 0.05; ##P < 0.01). (G) Signals from e.g., activated RTK and βAR cascades
converge on the Rac:PKA complex leading to modulation of the MAP kinase Erk1/2. GTP-Rac interacts with its main effectors p21-activated kinases (PAK1-6),
but it stabilizes the inactive PKA-holoenzyme (R:C). βAR-controlled cAMP elevation promotes PKA–mediated phosphorylation of GTP-Rac1–bound and GTP-
Rac1–activated PAK that contributes to elevations of Erk1/2 phosphorylation (P) that, in turn, enhances nuclear signaling leading to proliferation.
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physiological processes whereby PAK deregulation has been
implicated in oncogenesis (26, 44, 45). It has been described that
PAK4 activities regulate cancer cell proliferation, migration, and
invasion. Besides the abundance of PAK4, the phosphorylation of
PAK4-Ser474 has been determined as a crucial factor in cancer
progression (45). In this context, our research highlights a unique
route how βAR-provoked cAMP fluxes might participate, besides
PKA-mediated Erk1/2 modulation, in further diverse functions of
themiscellaneous Rac-effectors PAKs. Given that PAKs activities
are considered as marker for the prognosis of different types
of cancer, we would like to note that besides PAKs abundance
and its phosphorylation status, the GTP-Rac:PKA complex and
βAR activities need to be considered (16, 44, 45, 54). The disclo-
sure of the involvement of the βAR-PKA cascade in regulation of
Rac-PAK–mediated Erk1/2 activities offers an explanation how
cAMP fluxes contribute to cell growth in a cell-dependent manner.
Materials and Methods
Description of antibodies, protein purification, kinase assays, and farWestern
blots are in SI Materials and Methods. The Renilla luciferase-based PCA assay
has been described in detail previously (33). PCA assays, SPOT synthesis and
overlay experiments, cAMP-agarose precipitations and phosphorylation
assays have been described (18) and are in SI Materials and Methods.
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